Prostatis Group’s Merck MRK Stock Holding History

Prostatis Group’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$332K	Sell	2,757 -58	-2%	-$6.7K	0.08%	128
2025 Q4	$296K	Buy	+2,815	New	+$264K	0.07%	138
2025 Q1	–	Sell	-2,773	Closed	-$276K	–	158
2024 Q4	$276K	Sell	2,773 -693	-20%	-$71.4K	0.08%	131
2024 Q3	$394K	Sell	3,466 -105	-3%	-$12.5K	0.13%	102
2024 Q2	$442K	Buy	3,571 +677	+23%	+$87.2K	0.16%	100
2024 Q1	$382K	Sell	2,894 -167	-5%	-$20.6K	0.14%	103
2023 Q4	$334K	Sell	3,061 -296	-9%	-$30.7K	0.14%	101
2023 Q3	$376K	Sell	3,357 -172,568	-98%	-$18.6M	0.18%	74
2023 Q2	$349K	Buy	175,925 +167,711	+2,042%	+$19M	0.16%	83
2023 Q1	$891K	Sell	8,214 -31	-0.4%	-$3.35K	0.47%	52
2022 Q4	$915K	Buy	8,245 +5,758	+232%	+$589K	0.56%	45
2022 Q3	$214K	Buy	2,487 +125	+5%	+$11.2K	0.25%	60
2022 Q2	$215K	Buy	+2,362	New	+$209K	0.34%	42
2020 Q3	–	Sell	-4,570	Closed	-$337K	–	79
2020 Q2	$337K	Buy	+4,570	New	+$344K	0.68%	42

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prostatis Group's MRK Position: Q1 2026 in Review

Prostatis Group reduced its Merck (MRK) stake by 2.1% in Q1 2026, selling an estimated $6.7K and leaving 2,757 shares worth $332K. The position accounts for 0.08% of the portfolio, ranked #128.

Prostatis Group first reported a position in MRK in Q2 2020 and has held it in 14 quarters since. The position peaked at $915K in Q4 2022. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

Prostatis Group held 2,757 shares of Merck worth $332K as of Q1 2026.
Prostatis Group sold 58 Merck shares in Q1 2026, an estimated $6.7K.
Merck made up 0.08% of Prostatis Group's portfolio in Q1 2026, its #128 holding.
Prostatis Group first reported a position in Merck in Q2 2020 and has held it in 14 quarters since.
Prostatis Group's Merck position peaked at $915K in Q4 2022.
3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Prostatis Group's 13F filing for Q1 2026, filed 12 May 2026.